Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NUVB |
---|---|---|
09:32 ET | 26131 | 2.75 |
09:34 ET | 5195 | 2.76 |
09:36 ET | 16051 | 2.78 |
09:38 ET | 14150 | 2.755 |
09:39 ET | 1600 | 2.75 |
09:41 ET | 3800 | 2.7312 |
09:43 ET | 190 | 2.74 |
09:45 ET | 5948 | 2.745 |
09:48 ET | 2866 | 2.725 |
09:52 ET | 6810 | 2.755 |
09:54 ET | 200 | 2.755 |
09:56 ET | 3528 | 2.75 |
09:57 ET | 4797 | 2.725 |
09:59 ET | 500 | 2.7201 |
10:01 ET | 10552 | 2.73 |
10:03 ET | 4645 | 2.705 |
10:06 ET | 5356 | 2.675 |
10:08 ET | 200 | 2.675 |
10:10 ET | 2349 | 2.67 |
10:12 ET | 1448 | 2.675 |
10:14 ET | 12880 | 2.685 |
10:15 ET | 1227 | 2.685 |
10:17 ET | 600 | 2.685 |
10:19 ET | 300 | 2.68 |
10:21 ET | 3833 | 2.675 |
10:24 ET | 15643 | 2.685 |
10:26 ET | 550 | 2.685 |
10:28 ET | 200 | 2.685 |
10:30 ET | 100 | 2.685 |
10:32 ET | 18018 | 2.67 |
10:33 ET | 2733 | 2.6691 |
10:35 ET | 8371 | 2.66 |
10:37 ET | 16147 | 2.645 |
10:39 ET | 801 | 2.645 |
10:42 ET | 8880 | 2.645 |
10:44 ET | 100 | 2.645 |
10:46 ET | 750 | 2.645 |
10:48 ET | 300 | 2.645 |
10:50 ET | 700 | 2.64 |
10:51 ET | 6501 | 2.635 |
10:53 ET | 1033 | 2.635 |
10:55 ET | 2482 | 2.63 |
10:57 ET | 300 | 2.625 |
11:02 ET | 100 | 2.62 |
11:04 ET | 29600 | 2.635 |
11:06 ET | 3099 | 2.625 |
11:08 ET | 200 | 2.625 |
11:09 ET | 2166 | 2.625 |
11:11 ET | 200 | 2.625 |
11:13 ET | 1000 | 2.625 |
11:15 ET | 900 | 2.625 |
11:18 ET | 6121 | 2.63 |
11:20 ET | 700 | 2.635 |
11:22 ET | 100 | 2.635 |
11:24 ET | 6279 | 2.645 |
11:26 ET | 600 | 2.645 |
11:27 ET | 300 | 2.645 |
11:29 ET | 1700 | 2.645 |
11:31 ET | 400 | 2.645 |
11:33 ET | 1633 | 2.645 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nuvation Bio Inc | 766.2M | -8.4x | --- |
Cogent Biosciences Inc | 765.9M | -3.4x | --- |
Viridian Therapeutics Inc | 762.7M | -2.6x | --- |
89Bio Inc | 777.2M | -4.0x | --- |
Prime Medicine Inc | 777.8M | -3.0x | --- |
Scholar Rock Holding Corp | 748.9M | -4.6x | --- |
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $766.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 247.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.42 |
EPS | $-0.31 |
Book Value | $2.76 |
P/E Ratio | -8.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.